From the miracle of vaccines to deindustrialization: Biontech closes factories and rewards shareholders.
The gold rush is officially over. Biontech , the company built on unprecedented financial success and the myth of its mRNA vaccines against Covid, is now facing the harsh reality of the post-pandemic market. Demand has naturally collapsed, and the economic consequences follow the classic, and often criticized, corporate finance script: actual production is sacrificed , the workforce is drastically reduced , and the remaining liquidity is channeled into share buybacks to support stock prices.
A look at the numbers reveals the true extent of this restructuring. The Mainz-based biotech company will cut up to 1,860 jobs , equivalent to a hefty 22% of its total workforce. The German production sites in Idar-Oberstein, Marburg, and Tübingen (the latter acquired just last year with the acquisition of rival CureVac for over a billion dollars), as well as the Singapore plant, will be closed by the end of 2027. In the first quarter of this year, the company already posted a net loss of 532 million euros.
From a macroeconomic and Keynesian perspective, this is a severe blow to the industrial fabric. Vaccine production, once celebrated as a strategic triumph for Europe, will be entirely outsourced and sold to its American partner, Pfizer. And while real manufacturing jobs are disappearing, management is calmly announcing a billion-dollar share buyback program. As Roland Strasser of the IGBCE union bitterly summarized, production capacity is being unscrupulously sacrificed just to impress and please shareholders.
Biontech's restructuring in brief:
| Indicator | Value / Impact |
| Jobs at risk | Up to 1,860 (22% of the workforce) |
| Sites closing down | Idar-Oberstein, Marburg, Tübingen, Singapore |
| Expected operational savings | 500 million euros per year (by 2029) |
| Share buyback | $1 billion (capital outflow to shareholders) |
Adding to this picture is the remarkable timing at the top. The founders, Ugur Sahin and Özlem Türeci, the golden couple of the pandemic, will leave the company by the end of the year to dedicate themselves, they say, to new independent research projects. After leading Biontech through the most profitable years in its history, they are leaving the thankless task of social slaughter and cuts to others.
Economically speaking, this case exemplifies the weaknesses of an overly financialized economy. Instead of reinvesting the massive accumulated profits (the company still sits on €16.7 billion in liquidity) to maintain and convert European production capacity, the company prefers to divert the profits to Wall Street or distribute them to investors. The loss of industrial expertise is evident: Europe, which had gone to great lengths to keep production on its soil, finds itself drained of related industries and expertise in favor of US giants. Biontech is shrinking to please the stock market, focusing on the risky oncology bet, but now it's workers and the real German economy who are paying the tangible price.
The article From the miracle of vaccines to deindustrialization: Biontech closes factories and rewards shareholders comes from Scenari Economici .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/dal-miracolo-dei-vaccini-alla-deindustrializzazione-biontech-chiude-le-fabbriche-e-premia-gli-azionisti/ on Wed, 06 May 2026 05:15:28 +0000.